Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Expert Panel Mixed on Macroeconomic Indexing of Drug Cost; Govt Urged to Quit Targeting Pharma for Savings
April 5, 2023
-
BUSINESS 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
-
COMMENTARY Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
BUSINESS Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
-
ACADEMIA Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
-
REGULATORY Audit Questions Rationale for Order of 882 Million COVID Vaccine Doses
March 30, 2023
-
REGULATORY Japan’s Foreign Minister Likely to Visit China Soon, Demand Citizen’s Release
March 29, 2023
-
REGULATORY Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
-
BUSINESS Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
-
ORGANIZATION Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
-
REGULATORY Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
-
REGULATORY MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
-
REGULATORY Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
BUSINESS CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
-
BUSINESS Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
-
BUSINESS Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
-
BUSINESS Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
-
BUSINESS Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
-
BUSINESS AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
-
ORGANIZATION PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…